Unlock instant, AI-driven research and patent intelligence for your innovation.
Application of Gypensapogenin A to preparing drugs for treating yellow fever virus infection
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A yellow fever virus and drug technology, applied in the field of biomedicine, to achieve huge social benefits and research value
Active Publication Date: 2013-01-16
南通三聚知识产权服务有限公司
View PDF0 Cites 1 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
So far, there have been no cases reported in China, but this does not make us relax our vigilance against the virus, because China's climate and geographical environment are complex, and there are many types of mosquitoes, which have the conditions for transmission. At the same time, with the increasing frequency of international exchanges, YFV It is very likely that it will be introduced into China
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0036] Embodiment 1: the preparation of the compound Gypensapogenin A tablet involved in the present invention:
[0037] Take 20 grams of compound Gypensapogenin A, add 180 grams of conventional excipients for tablet preparation, mix well, and make 1000 tablets with a conventional tabletting machine.
Embodiment 2
[0038] Embodiment 2: The preparation of the compound Gypensapogenin A capsules involved in the present invention:
[0039] Get 20 grams of compound Gypensapogenin A, add conventional auxiliary materials such as starch 180 grams for the preparation of capsules, mix well, and pack into capsules to make 1000 tablets.
[0040] The following pharmacodynamic experiments will further illustrate its drug activity.
experiment example 1
[0042] A kind of application of Gypensapogenin A in the preparation treatment or prevention yellow fever virus infectionmedicine, its steps are:
[0043] A. Toxicity test of Gypensapogenin A on Vero cells
[0046] 1: Inoculate Vero cells: Use DMEM medium containing 10% (v / v) fetal bovine serum to make a single cell suspension, inoculate 1000-10000 cells per well into a 96-well cell culture plate, and inoculate a volume of 100ul per well ;
[0047] 2: Culture Vero cells: at 37°C, 5% (v / v) CO 2 Under culture conditions, cultivate for 2 days;
[0048] 3: Add Gypensapogenin A: Discard the DMEM medium in each well, add 100ul to each well and dilute to the corresponding concentration (0uM, 0.4uM, 1.2 uM, 3.7uM, 11uM, 33uM, 100uM, 300uM) Gypensapogenin A, add 100ul of DMEM medium without 10% (v / v) fetal bovine serum to the control well;
[0049]...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention discloses application of Gypensapogenin A to preparing drugs for treating or preventing yellow fevervirus infection. Gypensapogenin A is capable of effectively inhibiting the proliferation of yellow fevervirus, has little toxicity to cells, can be further developed as the drugs for treating diseases caused by virus infection and has extensive application prospect. The application of Gypensapogenin A to preparing the drugs for treating the yellow fever virus infection, disclosed by the invention, is firstly published, the framework type is brand new, the activity of inhibiting the yellow fever virus is unexpectedly strong and the probability of giving any revelation by other compounds does not exist, so that prominent substantive features are provided and a remarkable progress in preventing and treating the yellow fever virus infection is made at the same time.
Description
technical field [0001] The invention belongs to the field of biomedicine, and more specifically relates to the application of Gypensapogenin A in the preparation of medicines for treating or preventing yellow fever virus infection. Background technique [0002] Yellow fever virus (YFV) is a member of the Flavivirusgenus in the family Flaviviridae. Yellow fever virus causes yellow fever, an acute infectious disease. Yellow fever has been designated as a quarantine infectious disease internationally, and China has also designated it as a Class A infectious disease. In 1648, an epidemic of yellow fever was first confirmed in the weekly YUCATAN peninsula. From the 17th to the 19th century, the disease was brought to Europe and North America through transportation. In almost two centuries, yellow fever became one of the most serious plagues in some parts of the United States, Africa, and Europe, causing a large number of deaths. Since the 20th century, the disease has not occ...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More 
